ELEVATED SERUM α‐HYDROXYBUTYRATE DEHYDROGENASE IN PATIENTS WITH OVARIAN CARCINOMA

Abstract. To differentiate between ovarian carcinoma and benign ovarian tumor, we compared a‐hydroxybutyrate de‐hydrogenase (HBD), lactate dehydrogenase (LDH) and its isoenzyme activities in serum in 115 patients with ovarian carcinoma and benign ovarian tumor. Both serum HBD activity and total LDH activity in ovarian cancer patients were significantly (p< 0.001) higher than that in patients with benign ovarian tumor. From analysis of serum LDH isoen‐zymes, a significant decrease in LDH‐1, and significant increases in LDH‐4 and LDH‐5 in ovarian cancer patients were observed, when compared with those in patients with benign ovarian tumor. When the ovarian cancer mass could be removed surgically, a significant decrease in the HBD was observed, suggesting that the HBD might fairly reflect the tumor burden. Serum HBD activities in a half of ovarian cancer patients were higher than the mean + 2 SD of those in benign control subjects.

[1]  E. Mackay,et al.  A multiparametric approach to tumor markers detectable in serum in patients with carcinoma of the ovary or uterine cervix. , 1980, Gynecologic oncology.

[2]  M. Rassam,et al.  Kinetics of lactate dehydrogenase and other enzyme studies in human serum in leukemia. , 1979, Biochemistry and experimental biology.

[3]  A. Malkin,et al.  Carcinoembryonic antigen (CEA) and other tumor markers in ovarian and cervical cancer , 1978, Cancer.

[4]  N. Zamcheck,et al.  Carcinoembryonic antigen and phosphohexose isomerase, gammaglutamyl transpeptidase and lactate dehydrogenase levels in patients with and without liver metastases , 1976, Cancer.

[5]  A. Schwartz,et al.  Serum lactic dehydrogenase and ovarian carcinoma , 1975 .

[6]  R. Galen,et al.  Diagnosis of acute myocardial infarction. Relative efficiency of serum enzyme and isoenzyme measurements. , 1975 .

[7]  A. Neville,et al.  The contribution of serum enzymes and carcinoembryonic antigen to the early diagnosis of metastatic colorectal cancer. , 1975, British Journal of Cancer.

[8]  A. Jandová,et al.  Activity of lactate dehydrogenase (L-Lactate: NAD oxidoreductase 1.1.1.27) in carcinomatous endometrial and cervical tissues. , 1974, Neoplasma.

[9]  G. Awais.  Serum lactic dehydrogenase levels in the diagnosis and treatment of carcinoma of the ovary. , 1973, American journal of obstetrics and gynecology.

[10]  T. Sugimura,et al.  Hexokinase isozyme patterns of human uterine tumors , 1972, Cancer.

[11]  C. Griffiths,et al.  Advanced ovarian cancer: Primary treatment with surgery, radiotherapy, and chemotherapy , 1972, Cancer.

[12]  G. Ellis,et al.  Serum -hydroxybutyrate dehydrogenase activity: an improved method. , 1971, American journal of clinical pathology.

[13]  W. Roman.  Quantitative estimation of lactate dehydrogenase isoenzymes in serum. I. Review of methods and distribution in human tissues. , 1969, Enzymologia.

[14]  H. Zondag,et al.  CLINICAL APPLICATIONS OF LACTATE DEHYDROGENASE ISOZYMES: ALTERATIONS IN MALIGNANCY , 1968, Annals of the New York Academy of Sciences.

[15]  E. Coodley.  CURRENT STATUS OF ENZYME DIAGNOSIS IN CARDIOVASCULAR DISEASE , 1966, The American journal of the medical sciences.

[16]  G. Kessler,et al.  Automated determination of NAD-coupled enzymes. Determination of lactic dehydrogenase☆ , 1965 .

[17]  J. H. Wilkinson,et al.  Serum α-Hydroxybutyrate Dehydrogenase in Diagnosis , 1964 .

[18]  J. H. Wilkinson,et al.  SERUM ALPHA-HYDROXYBUTYRATE DEHYDROGENASE IN DIAGNOSIS. , 1964, JAMA.

[19]  J. H. Wilkinson,et al.  SERUM "α-HYDROXYBUTYRIC DEHYDROGENASE" IN MYOCARDIAL INFARCTION AND IN LIVER DISEASE , 1961 .